Variant | Gene | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||
---|---|---|---|---|---|---|---|---|---|---|
|
0.780 | GeneticVariation | BEFREE | Stratified analysis by cancer type indicated the rs351855 G>A polymorphism was associated with an increased risk of breast and prostate cancer, but a decreased risk of lung cancer. | 28445975 | 2017 |
||||
|
0.780 | GeneticVariation | BEFREE | Three common polymorphisms (rs1966265, rs2011077, and rs351855) of FGFR4 were genotyped from 346 patients with prostate cancer by using the Sequenom MassARRAY system. | 27640814 | 2016 |
||||
|
0.780 | GeneticVariation | BEFREE | Gly-388Arg polymorphism of FGFR-4 most likely contributes to susceptibility to prostate cancer, especially in men of European descent. | 21625079 | 2011 |
||||
|
0.780 | GeneticVariation | BEFREE | This meta-analysis showed the evidence that FGFR4 Gly388Arg polymorphism was associated with an increased risk of prostate cancer development and progression, suggesting that FGFR4 Gly388Arg polymorphism could be a marker for prostate cancer development and progression. | 21349172 | 2011 |
||||
|
0.780 | GeneticVariation | BEFREE | The single nucleotide polymorphism Gly(388)Arg in FGFR4 is not associated with increased risk of prostate cancer in Scottish men. | 19918264 | 2010 |
||||
|
0.780 | GeneticVariation | BEFREE | Subset analysis of cases that had undergone radical prostatectomy revealed an association between rs351855 and prostate cancer risk. | 18762813 | 2009 |
||||
|
0.780 | GeneticVariation | BEFREE | Our results indicate that the FGFR4 Arg allele of the Gly388Arg polymorphism and the G allele of the rs2011077 polymorphism have a significant impact on the development of prostate cancer and BPH, and the progression of prostate cancer in a Japanese population. | 18756523 | 2008 |
||||
|
0.780 | GeneticVariation | BEFREE | The Gly388Arg polymorphism in the FGFR4 gene was reported to modulate cancer cell migration in vitro and to be associated with breast, colon, and prostate cancer prognostic parameters. | 16061909 | 2005 |